Focus: Design Therapeutics is a public biotech company focused on drugs targeting nucleotide-repeat expansion disorders, with a diversified pipeline spanning oncology, neurology, infectious diseases, cardiovascular, and respiratory indications. The company operates at mid-cap scale with 201-500 employees and is listed on NASDAQ under ticker DSGN.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Design Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Design Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Design Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks - TradingView
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks TradingView
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 Seeking Alpha
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program - Seeking Alpha
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program Seeking Alpha
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index marketscreener.com
FDA Launches Expedited IND Pilot, Begins Accepting Applications
The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot.
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92% - GEX Level - dars.gov.et
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92% - GEX Level dars.gov.et
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo